Latest news from Amphista

Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia

Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22

Amphista Therapeutics discloses first details of its SMARCA2 degrader program

Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment

Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel Targeted Glue™ degraders at SLAS Europe 2025

Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences